NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ADAP Stock Alerts $1.13 +0.12 (+11.88%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.04▼$1.1850-Day Range$0.90▼$1.5852-Week Range$0.42▼$2.05Volume14.92 million shsAverage Volume995,907 shsMarket Capitalization$278.91 millionP/E RatioN/ADividend YieldN/APrice Target$2.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Adaptimmune Therapeutics alerts: Email Address Adaptimmune Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside146.7% Upside$2.79 Price TargetShort InterestHealthy1.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.67) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector607th out of 928 stocksBiological Products, Except Diagnostic Industry96th out of 153 stocks 3.2 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.39% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 2.27%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 3.1 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows4 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 11.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More ADAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAP Stock News HeadlinesMay 30 at 4:01 PM | globenewswire.comGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsMay 30 at 8:22 AM | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at ScotiabankMay 23, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cooper Co (COO), Neurocrine (NBIX) and Arcturus Therapeutics (ARCT)May 20, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday TradingMay 16, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comAdaptimmune Q1 2024 Earnings PreviewMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)April 29, 2024 | finance.yahoo.comGlobal CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & PhaseApril 26, 2024 | seekingalpha.comAdaptimmune: Huge Opportunity Amid Their Setback With GenentechApril 26, 2024 | bizjournals.comGenentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to matchApril 24, 2024 | money.usnews.comAdaptimmune Therapeutics Plc - ADRApril 24, 2024 | finance.yahoo.comGarry Menzel joins GHO Capital as Operating PartnerApril 19, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week DownApril 16, 2024 | markets.businessinsider.comMaintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration TerminationApril 12, 2024 | bizjournals.comAdaptimmune shares drop as Genentech terminates potential $3B dealApril 12, 2024 | msn.comAdaptimmune falls as Roche strategic collaboration endsMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)March 15, 2024 | benzinga.comPeter W. Sonsini's Net WorthMarch 15, 2024 | finance.yahoo.comADAP Sep 2024 2.500 putMarch 13, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday TradingMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)March 8, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call TranscriptSee More Headlines Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today6/01/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees449Year FoundedN/APrice Target and Rating Average Stock Price Target$2.79 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+146.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-890.13% Pretax Margin-883.39% Return on Equity-259.68% Return on Assets-61.31% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual Sales$60.28 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book11.30Miscellaneous Outstanding Shares246,820,000Free Float216,120,000Market Cap$278.91 million OptionableOptionable Beta2.44 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Adrian G. Rawcliffe (Age 52)CEO, Principal Accounting Officer & Director Comp: $693.64kMr. Gavin Hilary James Wood ACA (Age 54)BA (Hons), Chief Financial Officer Comp: $508.22kMr. William C. Bertrand Jr. (Age 59)Esq., J.D., Chief Operating Officer Comp: $573.8kDr. Elliot Norry B.A. (Age 60)M.D., Chief Medical Officer Comp: $549.05kMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer Comp: $597.44kDr. Helen Katrina Tayton-Martin MBA (Age 57)Ph.D., Co-Founder & Chief Business & Strategy Officer Comp: $709.84kMs. Joanna Brewer Ph.D. (Age 48)Chief Scientific Officer Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsMs. Kerry SharpSenior VP & General CouncilDana LynchSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENCellectisNASDAQ:CLLSbluebird bioNASDAQ:BLUEAtara BiotherapeuticsNASDAQ:ATRACelyad OncologyNASDAQ:CYADView All CompetitorsInsiders & InstitutionsBaker BROS. Advisors LPSold 182,260 shares on 5/15/2024Ownership: 4.370%Boulder Hill Capital Management LPBought 90,800 shares on 5/14/2024Ownership: 0.037%GSA Capital Partners LLPSold 138,629 shares on 5/3/2024Ownership: 0.150%Baillie Gifford & Co.Sold 40,265 shares on 5/1/2024Ownership: 6.431%JTC Employer Solutions Trustee LtdBought 26,156 shares on 4/19/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions ADAP Stock Analysis - Frequently Asked Questions Should I buy or sell Adaptimmune Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares. View ADAP analyst ratings or view top-rated stocks. What is Adaptimmune Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.79 in the next year. This suggests a possible upside of 146.7% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts. How have ADAP shares performed in 2024? Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of the year. Since then, ADAP stock has increased by 42.5% and is now trading at $1.13. View the best growth stocks for 2024 here. When is Adaptimmune Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ADAP earnings forecast. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.12. The biotechnology company earned $0.23 million during the quarter, compared to the consensus estimate of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative trailing twelve-month return on equity of 259.68%. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG). When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.43%), Baker BROS. Advisors LP (4.37%), GSA Capital Partners LLP (0.15%), Key Client Fiduciary Advisors LLC (0.03%), Boulder Hill Capital Management LP (0.04%) and JTC Employer Solutions Trustee Ltd (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADAP) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.